Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
ESMC's Cash to Debt is ranked higher than
98% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. ESMC: No Debt )
ESMC' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.44
ESMC's Equity to Asset is ranked higher than
54% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ESMC: 0.44 )
ESMC' s 10-Year Equity to Asset Range
Min: 0.02   Max: 0.97
Current: 0.44

0.02
0.97
Interest Coverage No Debt
ESMC's Interest Coverage is ranked higher than
82% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 235.10 vs. ESMC: No Debt )
ESMC' s 10-Year Interest Coverage Range
Min: 1.58   Max: 9999.99
Current: No Debt

1.58
9999.99
F-Score: 3
Z-Score: -9.96
M-Score: -2.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -7.04
ESMC's Operating margin (%) is ranked higher than
61% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. ESMC: -7.04 )
ESMC' s 10-Year Operating margin (%) Range
Min: -2300   Max: 22.17
Current: -7.04

-2300
22.17
Net-margin (%) -7.21
ESMC's Net-margin (%) is ranked higher than
61% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. ESMC: -7.21 )
ESMC' s 10-Year Net-margin (%) Range
Min: -2150   Max: 22.82
Current: -7.21

-2150
22.82
ROE (%) -23.89
ESMC's ROE (%) is ranked higher than
58% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. ESMC: -23.89 )
ESMC' s 10-Year ROE (%) Range
Min: -173.96   Max: 117.3
Current: -23.89

-173.96
117.3
ROA (%) -11.54
ESMC's ROA (%) is ranked higher than
59% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. ESMC: -11.54 )
ESMC' s 10-Year ROA (%) Range
Min: -65.52   Max: 30.83
Current: -11.54

-65.52
30.83
ROC (Joel Greenblatt) (%) -57.24
ESMC's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. ESMC: -57.24 )
ESMC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -621.05   Max: 90.16
Current: -57.24

-621.05
90.16
Revenue Growth (3Y)(%) -21.60
ESMC's Revenue Growth (3Y)(%) is ranked higher than
52% of the 340 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. ESMC: -21.60 )
ESMC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -29.3   Max: 150.9
Current: -21.6

-29.3
150.9
EBITDA Growth (3Y)(%) -59.00
ESMC's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. ESMC: -59.00 )
ESMC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -59   Max: 94.5
Current: -59

-59
94.5
EPS Growth (3Y)(%) -57.90
ESMC's EPS Growth (3Y)(%) is ranked higher than
53% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. ESMC: -57.90 )
ESMC' s 10-Year EPS Growth (3Y)(%) Range
Min: -76.2   Max: 80.1
Current: -57.9

-76.2
80.1
» ESMC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ESMC Guru Trades in Q4 2013

Jim Simons 203,700 sh (+0.15%)
» More
Q1 2014

ESMC Guru Trades in Q1 2014

Jim Simons 206,400 sh (+1.33%)
» More
Q2 2014

ESMC Guru Trades in Q2 2014

Jim Simons 212,900 sh (+3.15%)
» More
Q3 2014

ESMC Guru Trades in Q3 2014

Jim Simons 215,500 sh (+1.22%)
» More
» Details

Insider Trades

Latest Guru Trades with ESMC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.68
ESMC's P/B is ranked higher than
72% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. ESMC: 3.68 )
ESMC' s 10-Year P/B Range
Min: 0.3   Max: 51.5
Current: 3.68

0.3
51.5
P/S 0.93
ESMC's P/S is ranked higher than
90% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. ESMC: 0.93 )
ESMC' s 10-Year P/S Range
Min: 0.21   Max: 7.39
Current: 0.93

0.21
7.39
EV-to-EBIT -11.43
ESMC's EV-to-EBIT is ranked higher than
58% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 61.55 vs. ESMC: -11.43 )
ESMC' s 10-Year EV-to-EBIT Range
Min: -71.3   Max: 35.2
Current: -11.43

-71.3
35.2
Current Ratio 2.01
ESMC's Current Ratio is ranked higher than
63% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. ESMC: 2.01 )
ESMC' s 10-Year Current Ratio Range
Min: 0.51   Max: 27.33
Current: 2.01

0.51
27.33
Quick Ratio 1.08
ESMC's Quick Ratio is ranked higher than
55% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. ESMC: 1.08 )
ESMC' s 10-Year Quick Ratio Range
Min: 0.27   Max: 24.67
Current: 1.08

0.27
24.67

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 49.00
ESMC's Price/Net Current Asset Value is ranked higher than
75% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ESMC: 49.00 )
ESMC' s 10-Year Price/Net Current Asset Value Range
Min: 1.22   Max: 51.67
Current: 49

1.22
51.67
Price/Tangible Book 4.90
ESMC's Price/Tangible Book is ranked higher than
76% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 6.92 vs. ESMC: 4.90 )
ESMC' s 10-Year Price/Tangible Book Range
Min: 0.61   Max: 101
Current: 4.9

0.61
101
Price/Median PS Value 1.41
ESMC's Price/Median PS Value is ranked higher than
65% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. ESMC: 1.41 )
ESMC' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 65.29
Current: 1.41

0.31
65.29
Earnings Yield (Greenblatt) -8.70
ESMC's Earnings Yield (Greenblatt) is ranked higher than
55% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ESMC: -8.70 )
ESMC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.8   Max: 45.5
Current: -8.7

2.8
45.5
Forward Rate of Return (Yacktman) 0.32
ESMC's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 5.52 vs. ESMC: 0.32 )
ESMC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -67.7   Max: 7.8
Current: 0.32

-67.7
7.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:ES4.Germany,
Escalon Medical Corp. ( 'Escalon') is a Pennsylvania corporation initially incorporated in California in 1987 and reincorporated in Pennsylvania in November 2001. The Company operates in the healthcare market specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the areas of ophthalmology, diabetes, hematology and vascular access. Drew is a diagnostics Company specializing in the design, manufacture and distribution of instruments for blood cell counting and blood analysis. Drew is focused on providing instrumentation and consumables for the physician office and veterinary office laboratories. Drew sells two diabetic testing products: the DS5 and the Hb-Gold. The DS5 instrument, dispenser and associated reagent kit measure long-term glucose control in diabetic patients. Drew offers a array of equipment for use in the field of human and veterinary hematology. Sonomed develops, manufactures and markets ultrasound systems for diagnostic or biometric applications in ophthalmology. The systems are of four types: A-Scans, B-Scans, High Frequency B-Scans ( 'UBMs') and pachymeters. The A-Scan provides information about the internal structure of the eye by sending a beam of ultrasound along a fixed axis through the eye and displaying the various echoes reflected from the surfaces intersected by the beam. The B-Scan is a diagnostic tool that supplies information to physicians where the media within the eye are cloudy or opaque. The UBM is a high frequency/high resolution ultrasound device, designed to provide highly detailed information of the anterior segment of the eye. The pachymeter uses the same principles as the A-Scan, but the system is tailored to measure the thickness of the cornea. The Company distributes two intraocular gas products C3F8 and SF6, which are used by vitreoretinal surgeons as a temporary tamponade in detached retina surgery. The Company conducts development of medical devices for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology at the Company's Dallas, Texas, Miami, Florida and Rennes, France facilities. The Company conducts medical device and vascular access product development at its New Berlin, Wisconsin facility. The Company has 13 United States patents and 28 patents issued abroad that cover the Company's surgical products and pharmaceutical technology. The Company's competitors include ophthalmic-oriented companies that market a broad portfolio of products, including prescription ophthalmic pharmaceuticals, ophthalmic devices, consumer products and other eye care products; large integrated pharmaceutical companies that market a limited number of ophthalmic pharmaceuticals in addition to many other pharmaceuticals; and smaller specialty pharmaceutical and biotechnology companies. The Company's products are subject to stringent ongoing regulation by the FDA and similar health authoritie
» More Articles for ESMC

Headlines

Articles On GuruFocus.com
Escalon Medical Corp. Reports Operating Results (10-Q) Nov 15 2010 
Escalon Medical Corp. Reports Operating Results (10-K) Oct 12 2010 
Escalon Medical Corp. Reports Operating Results (10-Q) May 20 2010 
Escalon Medical Corp. Reports Operating Results (10-Q) Nov 16 2009 
Escalon Medical Corp. Reports Operating Results (10-Q) May 15 2009 
Escalon Medical Corp. Reports Operating Results (10-Q) Feb 17 2009 

More From Other Websites
ESCALON MEDICAL CORP Financials Nov 22 2014
Escalon® Medical Corp. Reports First Quarter Fiscal 2015 Results Nov 18 2014
10-Q for Escalon Medical Corp. Nov 16 2014
ESCALON MEDICAL CORP Files SEC form 10-Q, Quarterly Report Nov 14 2014
Escalon® Medical Corp. Reports First Quarter Fiscal 2015 Results Nov 14 2014
10-K for Escalon Medical Corp. Sep 28 2014
Escalon® Medical Corp. Reports Fiscal 2014 Results Sep 26 2014
ESCALON MEDICAL CORP Files SEC form 10-K, Annual Report Sep 26 2014
ESCALON MEDICAL CORP Files SEC form 10-Q, Quarterly Report May 14 2014
Escalon® Medical Corp. Reports Profit in the Third Quarter of Fiscal 2014 May 14 2014
Escalon® Medical Corp. Enters Agreement to Distribute Diaton Tonometer Apr 25 2014
Escalon Medical Corp receives FDA 510k clearance for Sonomed Escalon VuPad Apr 04 2014
Escalon® Medical Corp. Receives FDA 510(k) Clearance for the Sonomed Escalon VuPad™ Apr 04 2014
Escalon Medical Is An Overlooked Ophthalmology Pure Play On The Verge Of Profitability Mar 26 2014
Escalon® Medical Corp. Reports Second Quarter Fiscal 2014 Results; New Product Introductions... Feb 14 2014
ESCALON MEDICAL CORP Files SEC form 10-Q, Quarterly Report Feb 14 2014
ESCALON MEDICAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of... Jan 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK